301281 科源制药
已收盘 12-17 15:00:00
资讯
新帖
简况
科源制药：在海南设有子公司林恒药业
证券之星 · 12-10
科源制药：在海南设有子公司林恒药业
科源制药：三高和心血管原料药均有布局
证券之星 · 12-09
科源制药：三高和心血管原料药均有布局
科源制药35亿并购急刹车，“化药+中药”梦碎背后的三重风险
新浪证券 · 12-05
科源制药35亿并购急刹车，“化药+中药”梦碎背后的三重风险
科源制药（301281）披露关于收到深圳证券交易所《关于终止对山东科源制药股份有限公司发行股份购买资产并募集配套资金申请审核的决定》的公告，12月03日股价下跌2.91%
证券之星 · 12-03
科源制药（301281）披露关于收到深圳证券交易所《关于终止对山东科源制药股份有限公司发行股份购买资产并募集配套资金申请审核的决定》的公告，12月03日股价下跌2.91%
科源制药最新公告：终止发行股份购买资产并募集配套资金暨关联交易事项
证券之星 · 11-28
科源制药最新公告：终止发行股份购买资产并募集配套资金暨关联交易事项
科源制药：不存在被实施退市风险警示的情形
证券之星 · 11-25
科源制药：不存在被实施退市风险警示的情形
科源制药：公司麻醉类产品为盐酸罗哌卡因原料药
证券之星 · 11-24
科源制药：公司麻醉类产品为盐酸罗哌卡因原料药
科源制药（301281）披露关于募集资金投资项目变更的议案，11月19日股价下跌2.33%
证券之星 · 11-19
科源制药（301281）披露关于募集资金投资项目变更的议案，11月19日股价下跌2.33%
科源制药（301281）披露召开2025年第四次临时股东会通知，11月03日股价上涨0.63%
证券之星 · 11-03
科源制药（301281）披露召开2025年第四次临时股东会通知，11月03日股价上涨0.63%
股市必读：科源制药(301281)股东户数1.11万户，较上期减少11.26%
证券之星 · 10-27
股市必读：科源制药(301281)股东户数1.11万户，较上期减少11.26%
科源制药（301281）2025年三季报简析：净利润同比下降20.7%，三费占比上升明显
证券之星 · 10-25
科源制药（301281）2025年三季报简析：净利润同比下降20.7%，三费占比上升明显
科源制药(301281)9月30日股东户数1.11万户，较上期减少11.26%
证券之星 · 10-24
科源制药(301281)9月30日股东户数1.11万户，较上期减少11.26%
科源制药股东问泽鸿累计减持270万股
财中社 · 09-19
科源制药股东问泽鸿累计减持270万股
科源制药（301281）披露召开2025年第三次临时股东大会通知，9月15日股价上涨0.31%
证券之星 · 09-15
科源制药（301281）披露召开2025年第三次临时股东大会通知，9月15日股价上涨0.31%
科源制药最新公告：发行股份购买资产交易通过市场监管总局反垄断审查
证券之星 · 09-05
科源制药最新公告：发行股份购买资产交易通过市场监管总局反垄断审查
科源制药8月19日现1笔大宗交易 总成交金额1860万元 溢价率为-17.00%
新浪证券-红岸工作室 · 08-19
科源制药8月19日现1笔大宗交易 总成交金额1860万元 溢价率为-17.00%
科源制药披露发行股份购宏济堂99.42%股权审核问询函回复
新浪财经-鹰眼工作室 · 08-18
科源制药披露发行股份购宏济堂99.42%股权审核问询函回复
科源制药(301281)6月30日股东户数1.25万户，较上期增加3.69%
证券之星 · 08-16
科源制药(301281)6月30日股东户数1.25万户，较上期增加3.69%
图解科源制药中报：第二季度单季净利润同比增34.54%
证券之星 · 08-16
图解科源制药中报：第二季度单季净利润同比增34.54%
科源制药：乐镜宇先生乃我国近代杰出的中药学专家，同时也是北京同仁堂乐家家族的第十二代传人
互动易 · 08-06
科源制药：乐镜宇先生乃我国近代杰出的中药学专家，同时也是北京同仁堂乐家家族的第十二代传人
加载更多
公司概况
公司名称：
山东科源制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-04-04
主营业务：
山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产和销售。公司的主要产品是化学原料药、化学药品制剂、中间体。
发行价格：
44.18
{"stockData":{"symbol":"301281","market":"SZ","secType":"STK","nameCN":"科源制药","latestPrice":26.54,"timestamp":1765955001000,"preClose":26.26,"halted":0,"volume":943554,"delay":0,"changeRate":0.0107,"floatShares":68852000,"shares":108000000,"eps":0.4824,"marketStatus":"已收盘","change":0.28,"latestTime":"12-17 15:00:00","open":26.13,"high":26.66,"low":25.87,"amount":24728200,"amplitude":0.0301,"askPrice":26.54,"askSize":49,"bidPrice":26.53,"bidSize":41,"shortable":0,"etf":0,"ttmEps":0.4824,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":26.26,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":28.89,"lowLimit":23.63,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108290000,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":55.016584,"roe":"2.3%","epsLYR":0.56,"committee":0.028721,"marketValue":2874000000,"turnoverRate":0.0137,"status":0,"floatMarketCap":1827000000},"requestUrl":"/m/hq/s/301281","defaultTab":"news","newsList":[{"id":"2590430643","title":"科源制药：在海南设有子公司林恒药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2590430643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590430643?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:06","pubTimestamp":1765350386,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司在海南省是否有子公司？是否在海南省有相关业务布局？科源制药回复：尊敬的投资者您好，公司在海南投资设有子公司海南林恒药业有限公司，主要业务为医药商业代理及配送服务，是公司在下游产业链的延伸。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000018887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2590318703","title":"科源制药：三高和心血管原料药均有布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590318703?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:21","pubTimestamp":1765264882,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司在三高和心血管原料药是否有布局，未来是否有考虑保健品原料药？科源制药回复：尊敬的投资者您好，公司产品聚焦慢病领域，三高和心血管原料药均有布局，目前降糖类主要原料药为格列齐特和盐酸二甲双胍，心血管类主要原料药为单硝酸异山梨酯，目前公司暂未布局保健品原料药，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900018308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2589895421","title":"科源制药35亿并购急刹车，“化药+中药”梦碎背后的三重风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2589895421","media":"新浪证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589895421?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:13","pubTimestamp":1764929580,"startTime":"0","endTime":"0","summary":"11月28日，科源制药召开董事会，宣布终止发行股份购买山东宏济堂99.42%股权的重大资产重组事项，同时撤回配套募集资金申请。这场自2024年10月启动、被视作“力诺系”内部医药资产整合关键一步的并购案，在历时一年多的推进后戛然而止。 科源制药在公告中将终止原因归咎于“市场整体环境发生变化”，强调此举是为保障全体股东长期利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-05/doc-infztyiy8312094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2588014544","title":"科源制药（301281）披露关于收到深圳证券交易所《关于终止对山东科源制药股份有限公司发行股份购买资产并募集配套资金申请审核的决定》的公告，12月03日股价下跌2.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014544","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014544?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:21","pubTimestamp":1764753686,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，科源制药报收于28.06元，较前一交易日下跌2.91%，最新总市值为30.39亿元。该股当日开盘28.9元，最高29.01元，最低27.86元，成交额达8185.63万元，换手率为4.21%。公司近日发布公告称，山东科源制药股份有限公司于2025年11月28日召开董事会，审议通过终止发行股份购买资产并募集配套资金暨关联交易事项，并向深圳证券交易所申请撤回相关文件。公司指定信息披露媒体为《上海证券报》《证券时报》《中国证券报》《证券日报》及巨潮资讯网。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300026837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239","399001"],"gpt_icon":0},{"id":"2586491785","title":"科源制药最新公告：终止发行股份购买资产并募集配套资金暨关联交易事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586491785?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:30","pubTimestamp":1764325844,"startTime":"0","endTime":"0","summary":"科源制药(301281.SZ)公告称，公司于2025年11月28日召开董事会审议通过终止发行股份购买资产并募集配套资金暨关联交易事项并撤回申请文件。原计划向力诺投资控股集团有限公司等38名交易对方发行股份购买山东宏济堂制药集团股份有限公司99.42%股份，并募集配套资金。终止原因为市场环境变化，为维护全体股东长期利益。公司承诺一个月内不再筹划重大资产重组事项。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800028204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2586247330","title":"科源制药：不存在被实施退市风险警示的情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2586247330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586247330?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:51","pubTimestamp":1764075102,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有退市风险？科源制药回复：尊敬的投资者您好，公司生产经营正常，不存在被实施退市风险警示的情形，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2585452625","title":"科源制药：公司麻醉类产品为盐酸罗哌卡因原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452625?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:36","pubTimestamp":1763973369,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的麻醉药市场占有率怎么样？谢谢！科源制药回复：尊敬的投资者您好，公司麻醉类产品为盐酸罗哌卡因原料药，用于生产麻醉注射剂，公司正在积极推进盐酸罗哌卡因的市场推广，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400018029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2584592947","title":"科源制药（301281）披露关于募集资金投资项目变更的议案，11月19日股价下跌2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584592947","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584592947?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:26","pubTimestamp":1763562386,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，科源制药报收于30.66元，较前一交易日下跌2.33%，最新总市值为33.2亿元。该股当日开盘31.39元，最高31.53元，最低30.51元，成交额达3072.12万元，换手率为1.45%。本次股东会于2025年11月19日以现场和网络投票方式召开，审议通过了《关于募集资金投资项目变更的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900040066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2580214933","title":"科源制药（301281）披露召开2025年第四次临时股东会通知，11月03日股价上涨0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580214933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580214933?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:39","pubTimestamp":1762180761,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，科源制药报收于32.04元，较前一交易日上涨0.63%，最新总市值为34.7亿元。该股当日开盘31.83元，最高32.17元，最低31.6元，成交额达3455.69万元，换手率为1.57%。近日，科源制药发布公告称，公司将于2025年11月19日15:30召开2025年第四次临时股东会，会议采取现场投票与网络投票相结合的方式进行。中小投资者表决将单独计票并披露。登记时间为2025年11月18日，可通过现场、信函或传真方式登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300036304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2578657157","title":"股市必读：科源制药(301281)股东户数1.11万户，较上期减少11.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578657157","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578657157?lang=zh_cn&edition=full","pubTime":"2025-10-27 04:58","pubTimestamp":1761512289,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，科源制药报收于31.59元，下跌2.86%，换手率3.08%，成交量2.12万手，成交额6718.01万元。来自股本股东变化：截至2025年9月30日股东户数环比减少11.26%，户均持股上升至9769股，筹码集中度进一步提高。股本股东变化股东户数变动近日科源制药披露，截至2025年9月30日公司股东户数为1.11万户，较6月30日减少1407.0户，减幅为11.26%。户均持股数量由上期的8669.0股增加至9769.0股，户均持股市值为33.58万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2578652579","title":"科源制药（301281）2025年三季报简析：净利润同比下降20.7%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2578652579","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578652579?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:11","pubTimestamp":1761343897,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期科源制药发布2025年三季报。截至本报告期末，公司营业总收入3.03亿元，同比下降8.52%，归母净利润3147.07万元，同比下降20.7%。按单季度数据看，第三季度营业总收入7482.21万元，同比下降20.18%，第三季度归母净利润-1121.24万元，同比下降412.15%。本报告期科源制药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.91%。然而去年的净利率为13%，算上全部成本后，公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"gpt_icon":0},{"id":"2577599549","title":"科源制药(301281)9月30日股东户数1.11万户，较上期减少11.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577599549","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577599549?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:18","pubTimestamp":1761297531,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科源制药披露，截至2025年9月30日公司股东户数为1.11万户，较6月30日减少1407.0户，减幅为11.26%。在化学制药行业个股中，科源制药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.23万户。从股价来看，2025年6月30日至2025年9月30日，科源制药区间涨幅为6.15%，在此期间股东户数减少1407.0户，减幅为11.26%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400030816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2568668752","title":"科源制药股东问泽鸿累计减持270万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2568668752","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568668752?lang=zh_cn&edition=full","pubTime":"2025-09-19 20:19","pubTimestamp":1758284340,"startTime":"0","endTime":"0","summary":"9月19日，科源制药（301281）发布公告，股东问泽鸿通过集中竞价和大宗交易方式累计减持270万股，占公司总股本的2.50%。2025年中期，科源制药实现收入2.28亿元，归母净利润4268万元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-19/doc-infqzuwe9538424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2567485021","title":"科源制药（301281）披露召开2025年第三次临时股东大会通知，9月15日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567485021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567485021?lang=zh_cn&edition=full","pubTime":"2025-09-15 22:20","pubTimestamp":1757946056,"startTime":"0","endTime":"0","summary":"公司于近日发布公告，宣布将于2025年9月29日15:00召开2025年第三次临时股东大会，会议采取现场投票与网络投票相结合方式，股权登记日为2025年9月23日。本次股东大会将审议多项议案，包括：调整发行股份购买资产并募集配套资金暨关联交易方案；修订相关报告书草案及摘要；变更经营范围、调整组织架构并修订公司章程；制定、修订部分治理制度；购买董监高责任险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500033267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2565142556","title":"科源制药最新公告：发行股份购买资产交易通过市场监管总局反垄断审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2565142556","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565142556?lang=zh_cn&edition=full","pubTime":"2025-09-05 17:28","pubTimestamp":1757064509,"startTime":"0","endTime":"0","summary":"科源制药(301281.SZ)公告称，公司拟通过发行股份方式购买山东宏济堂制药集团股份有限公司99.42%股权，同时募集配套资金。此次交易需经过国家市场监督管理总局反垄断局的审查方可实施。此次交易近日收到国家市场监督管理总局出具的《经营者集中反垄断审查不实施进一步审查决定书》，决定不实施进一步审查。公司此次交易尚需履行深交所审核通过并经中国证监会予以注册等程序。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500028955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2560616274","title":"科源制药8月19日现1笔大宗交易 总成交金额1860万元 溢价率为-17.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560616274","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560616274?lang=zh_cn&edition=full","pubTime":"2025-08-19 17:40","pubTimestamp":1755596400,"startTime":"0","endTime":"0","summary":" 8月19日，科源制药收涨0.16%，收盘价为37.35元，发生1笔大宗交易，合计成交量60万股，成交金额1860万元。 进一步统计，近3个月内该股累计发生4笔大宗交易，合计成交金额为2507.22万元。该股近5个交易日累计上涨3.03%，主力资金合计净流出811.69万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-08-19/doc-infmpiyz2544015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2560907258","title":"科源制药披露发行股份购宏济堂99.42%股权审核问询函回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2560907258","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560907258?lang=zh_cn&edition=full","pubTime":"2025-08-18 20:26","pubTimestamp":1755519960,"startTime":"0","endTime":"0","summary":"山东科源制药股份有限公司于2025年8月18日发布关于发行股份购买资产并募集配套资金申请的审核问询函回复的提示性公告。公告显示，科源制药拟通过发行股份方式购买山东宏济堂制药集团股份有限公司99.42%股权，并同时募集配套资金。科源制药表示将继续推进相关工作，并严格履行信息披露义务，所有信息以公司在深圳证券交易所指定信息披露媒体披露为准，提醒投资者关注后续公告，注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigc/wenxun/2025-08-18/doc-infmmfac8444584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2559421940","title":"科源制药(301281)6月30日股东户数1.25万户，较上期增加3.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559421940","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559421940?lang=zh_cn&edition=full","pubTime":"2025-08-16 17:04","pubTimestamp":1755335064,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科源制药披露，截至2025年6月30日公司股东户数为1.25万户，较3月31日增加445.0户，增幅为3.69%。在化学制药行业个股中，科源制药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.35万户。从股价来看，2025年3月31日至2025年6月30日，科源制药区间涨幅为0.09%，在此期间股东户数增加445.0户，增幅为3.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081600015485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2559943363","title":"图解科源制药中报：第二季度单季净利润同比增34.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559943363","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559943363?lang=zh_cn&edition=full","pubTime":"2025-08-16 01:43","pubTimestamp":1755279796,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药2025年中报显示，公司主营收入2.28亿元，同比下降3.91%；归母净利润4268.3万元，同比上升18.26%；扣非净利润3586.91万元，同比上升38.51%；其中2025年第二季度，公司单季度主营收入1.17亿元，同比上升28.39%；单季度归母净利润1959.82万元，同比上升34.54%；单季度扣非净利润1693.97万元，同比上升182.72%；负债率13.85%，投资收益373.51万元，财务费用-123.76万元，毛利率54.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081600000925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"gpt_icon":0},{"id":"2557232159","title":"科源制药：乐镜宇先生乃我国近代杰出的中药学专家，同时也是北京同仁堂乐家家族的第十二代传人","url":"https://stock-news.laohu8.com/highlight/detail?id=2557232159","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557232159?lang=zh_cn&edition=full","pubTime":"2025-08-06 16:27","pubTimestamp":1754468820,"startTime":"0","endTime":"0","summary":"有投资者向科源制药提问， 济堂的历史可以追溯到1907年，以下是其发展历程中的关键节点： - 1907年，北京同仁堂第十二代传人乐镜宇斥资取得山东官药局所有权，将其更名为“宏济堂”，确立了“宏仁广布、济世养生、堂正天下”的立堂宗旨。- 1909年，乐镜宇筹集资金创办宏济堂阿胶厂，独创“九昼夜提制法”，生产出独具特色的12种阿胶。- 1914年，宏济堂阿胶荣获山东省物产博览会贵公宏济堂与同仁堂传人有关联？公司回答表示，尊敬的投资者您好，宏济堂老号于1907 年由乐镜宇先生创立。乐镜宇先生乃我国近代杰出的中药学专家，同时也是北京同仁堂乐家家族的第十二代传人。感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080616381997371843&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080616381997371843&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0239","301281","LU1688375341.USD","BK0012","BK0196","BK0086","BK0097","BK0028","600085","BK0113","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765962806748,"stockEarnings":[{"period":"1week","weight":-0.0486},{"period":"1month","weight":-0.19},{"period":"3month","weight":-0.2531},{"period":"6month","weight":-0.137},{"period":"1year","weight":-0.2235},{"period":"ytd","weight":-0.1166}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东科源制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11085人(较上一季度减少11.26%)","perCapita":"6211股","listingDate":"2023-04-04","address":"山东省济南市商河县经济开发区科源街","registeredCapital":"10829万元","survey":" 山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产和销售。公司的主要产品是化学原料药、化学药品制剂、中间体。","listedPrice":44.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科源制药,301281,科源制药股票,科源制药股票老虎,科源制药股票老虎国际,科源制药行情,科源制药股票行情,科源制药股价,科源制药股市,科源制药股票价格,科源制药股票交易,科源制药股票购买,科源制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}